Corcept Therapeutics Incorporated
CORT
Ранг среди акций
#1694
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Цена акции
$116.87
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$12.63B
Изменение (1 день)
4.25%
Изменение (1 год)
55.01%
Страна
US
Торговля Corcept Therapeutics Incorporated (CORT)
Категория
Healthcare
Выручка компании Corcept Therapeutics Incorporated (CORT)
Выручка на Jun 2026 TTM: $830.81M
Согласно последним финансовым отчетам Corcept Therapeutics Incorporated, текущая выручка компании (TTM) составляет $830.81M. В 2023 году компания получила выручку $482.38M больше, чем выручке в 2022 году, которая составила $401.86M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Corcept Therapeutics Incorporated с 2001 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $830.81M | 23.08% |
| 2024 | $675.04M | 39.94% |
| 2023 | $482.38M | 20.04% |
| 2022 | $401.86M | 9.80% |
| 2021 | $365.98M | 3.42% |
| 2020 | $353.87M | 15.46% |
| 2019 | $306.49M | 21.99% |
| 2018 | $251.25M | 57.82% |
| 2017 | $159.20M | 95.77% |
| 2016 | $81.32M | 61.72% |
| 2015 | $50.29M | 89.39% |
| 2014 | $26.55M | 156.36% |
| 2013 | $10.36M | 213.18% |
| 2012 | $3.31M | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | $29.00K | -86.12% |
| 2008 | $209.00K | -56.64% |
| 2007 | $482.00K | 63.95% |
| 2006 | $294.00K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $2.54B | 205.24% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $4.88B | 487.88% |
HK
|
